Immunocore Holdings plc (ADR) share price logo

Immunocore Holdings plc (ADR)

NASDAQ: IMCR

Small Cap

$34.21

+0.01

(+0.03%)

as on

Immunocore Holdings plc (ADR) Stock Performance

as on August 15, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $33.50
    $34.39
    downward going graph

    2.08%

    Downside

    0.53%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $27.56
    $40.71
    downward going graph

    19.45%

    Downside

    19.01%

    Upside

    downward going graph

Immunocore Holdings plc (ADR) share price movements today

Previous Close
$34.20
Open
$34.01
Volume
199.8K
Day's Low - High
$33.50 - $34.39
52 Week Low - High
$27.56 - $40.71

Immunocore Holdings plc (ADR) Historical Returns

1 Month Return
+ 2.18 %
3 Month Return
+ 18.92 %
1 Year Return
+ 3.45 %
3 Year Return
-43.66 %
5 Year Return
+ 11.33 %

Immunocore Holdings plc (ADR) Stock Fundamentals & Key Indicators

Check Immunocore Holdings plc (ADR) market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.8B

EPS (TTM)

-0.069

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

1.50%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

756.0K

Revenue (TTM)

430.8M

Profit Margin

-4.20%

Return On Equity TTM

-4.47%

Immunocore Holdings plc (ADR) vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Immunocore Holdings plc (ADR) with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Immunocore Holdings plc (ADR) image
Immunocore Holdings plc (ADR)
BUY$1.8B11.33%NA-4.20%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$44.0B690.3%NA0.00%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$133.3B165.71%30.8735.00%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$82.2B29%19.7227.87%0.45999999999999996%

Stock Returns calculator for Immunocore Holdings plc (ADR) Stock including INR - Dollar returns

The Immunocore Holdings plc (ADR) stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Immunocore Holdings plc (ADR) investment value today

Current value as on today

₹1,13,101

Returns

₹13,101

(+13.1%)

Returns from Immunocore Holdings plc (ADR) Stock

₹3,479 (+3.48%)

Dollar Impact

₹9,622 (+9.62%)

Analyst Recommendation on Immunocore Holdings plc (ADR) Stock

Based on 24 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 24 analysts, 91.67% of analysts recommend a 'BUY' rating for Immunocore Holdings plc (ADR). Average target price of $63.63

Immunocore Holdings plc (ADR) Share Price Target

Get share price movements and forecasts by analysts on Immunocore Holdings plc (ADR).

What analysts predicted

46.24%UPSIDE

Target Price

$63.63

Current Price

$34.21

Analyzed by

24 Analysts

Target

$63.63

Immunocore Holdings plc (ADR) target price $63.63, a slight upside of 46.24% compared to current price of $34.21. According to 24 analysts rating.

Indian Investors' Interest in Immunocore Holdings plc (ADR) Stock

Search interest for Immunocore Holdings plc (ADR) Stock has increased by 156% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:156% versus previous 30 day period

Immunocore Holdings plc (ADR) Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
89
75
80
84
93
97
103
77
106
115
Gross Profit
89
73
79
83
93
96
103
74
106
114
Operating Income
-26
-16
-8
-19
-3
-14
-7
-14
7
-2
EBITDA
-19
-5
10
-15
9
-6
4
-8
16
3
Interest Expense
3
3
3
6
3
3
3
3
2
3
Depreciation
1
0
1
1
0
0
0
0
0
1
Income Before Tax
-24
-10
6
-24
6
-9
0
-11
13
0
Income Tax Expense
0
1
-2
-1
1
0
0
10
0
0
Net Income
-31
-11
8
-23
5
-10
0
-22
12
0
Net Profit Margin
-34.66%
-15.41%
10.89%
-28.28%
5.35%
-10.51%
0.76%
-28.77%
12.16%
-0.70%

Immunocore Holdings plc (ADR) Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
20
19
29
33
40
35
175
249
247
297
Gross Profit
20
19
29
-97
-60
35
169
248
242
291
Operating Income
-32
-67
-93
-118
-86
-129
-42
-47
-56
-33
EBITDA
-29
-64
-86
-111
-82
-123
-38
-40
-38
0
Interest Expense
-
-
0
3
3
5
5
4
18
12
Depreciation
-
-
6
9
8
7
6
5
4
3
Income Before Tax
-31
-64
-88
-81
-87
-133
-33
-48
-42
-14
Income Tax Expense
8
15
-16
22
-13
0
9
-4
-1
12
Net Income
-28
-66
-90
-136
-99
-177
-52
-55
-40
-26
Net Profit Margin
-140.50%
-343.13%
-302.82%
-404.89%
-246.04%
-493.45%
-30.13%
-22.17%
-16.45%
-8.88%

Immunocore Holdings plc (ADR) Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-11
8
-23
5
-10
0
-30
12
0
Operating Cash Flow
23
21
-13
0
25
-4
-32
-13
-5
Investing Cash Flow
-350
0
-3
9
-30
5
0
4
0
Financing Cash Flow
0
0
-51
2
3
1
4
0
15
Change in Cash
-327
32
-82
21
11
10
-30
-15
15

Immunocore Holdings plc (ADR) Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-49
-71
-103
-74
-180
-52
-34
-51
-26
Operating Cash Flow
-61
-16
-101
-60
-143
-49
2
26
-7
Investing Cash Flow
-9
58
-4
0
-1
-2
-4
-355
-12
Financing Cash Flow
19
0
55
115
288
145
27
343
9
Change in Cash
-52
41
-50
55
144
81
31
13
8

Global Institutional Holdings in Immunocore Holdings plc (ADR)

Funds
Holdings
FMR Inc
9.49%
Caption Management, LLC
1.3%
Bellevue Group AG
5.5%
Citigroup Inc
1.26%
Logos Global Management LP
2.95%
See all

Immunocore Holdings plc (ADR) News & Key Events

  • img

    Today's Timeline - 10 August

    Mon, 09:46 PM

    -

    Immunocore reports Q2 2026 revenues of $115.9 million, up 18.3% year over year, driven by Kimmtrak sales.

Insights on Immunocore Holdings plc (ADR)

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 77.42M → 115.92M (in $), with an average increase of 17.7% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, IMCR stock has moved up by 22.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 581.3% return, outperforming this stock by 624.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 460.9% return, outperforming this stock by 456.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 12.97M → -808.0K (in $), with an average decrease of 106.2% per quarter

About Immunocore Holdings plc (ADR)

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
OrganisationImmunocore Holdings plc (ADR)
Headquarters92 Park Drive, Abingdon, United Kingdom, OX14 4RY
IndustryBiotechnology
CEODr. Bahija Jallal Ph.D.
E-voting on sharesClick here to vote

Key Management of Immunocore Holdings plc (ADR)

Name

Title

Ms. Anne Achola Sefu

EVP, Chief Human Resources Officer & Director

Dr. Bahija Jallal Ph.D.

CEO & Executive Director

Mr. Travis Alan Coy M.B.A.

CFO, Executive VP & Head of Corporate Development

Ms. Annelise Vuidepot Ph.D.

Chief Science and Technology Officer & Milton Park Site Head

Ms. Lily Margaret Hepworth

Executive VP, General Counsel & Company Secretary

Ms. Elizabeth Varki Jobes Esq., J.D.

Chief Compliance Officer

Mr. Sébastien Desprez

Vice President of Communications

Dr. Kripa Ram Ph.D.

Executive VP & Chief Operating Officer

Mr. John Goll III

SVP, Finance & Chief Accounting Officer

Mr. Sean D. Buckley

VP & Chief Information Officer

FAQs

What is Immunocore Holdings plc (ADR) share price today?

Immunocore Holdings plc (ADR) share price today is $34.21 as on at the close of the market. Immunocore Holdings plc (ADR) share today touched a day high of $34.39 and a low of $33.50.

What is the 52 week high and 52 week low for Immunocore Holdings plc (ADR) share?

Immunocore Holdings plc (ADR) share touched a 52 week high of $40.71 on and a 52 week low of $27.56 on . Immunocore Holdings plc (ADR) stock price today i.e. is closed at $34.21,which is 15.98% down from its 52 week high and 24.15% up from its 52 week low.

What is Immunocore Holdings plc (ADR)'s market capitalisation today?

Immunocore Holdings plc (ADR) market capitalisation is $0.00T as on .

How to invest in Immunocore Holdings plc (ADR) Stock (IMCR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Immunocore Holdings plc (ADR) on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Immunocore Holdings plc (ADR) Shares that will get you 0.0438 shares as per Immunocore Holdings plc (ADR) share price of $34.21 per share as on August 15, 2026 at 8:45 am IST.

What is the minimum amount required to buy Immunocore Holdings plc (ADR) Stock (IMCR) from India?

Indian investors can start investing in Immunocore Holdings plc (ADR) (IMCR) shares with as little as ₹95.43 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹954.30 in Immunocore Holdings plc (ADR) stock (as per the Rupee-Dollar exchange rate as on ). Based on Immunocore Holdings plc (ADR) share’s latest price of $34.21 as on August 15, 2026 at 8:45 am IST, you will get 0.2923 shares of Immunocore Holdings plc (ADR). Learn more about fractional shares .

What are the returns that Immunocore Holdings plc (ADR) has given to Indian investors in the last 5 years?

Immunocore Holdings plc (ADR) stock has given 11.33% share price returns and 28.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?